Amid the COVID-19 crisis, the global market for Radiopharmaceuticals estimated at US$5.9 Billion in the year 2020, is projected to reach a revised size of US$9.7 Billion by 2027, growing at a CAGR of 7.3% over the analysis period 2020-2027. SPECT Radioisotopes, one of the segments analyzed in the report, is projected to record a 7.3% CAGR and reach US$4.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the PET Radioisotopes segment is readjusted to a revised 7.7% CAGR for the next 7-year period.
The U.S. Market is Estimated at $1.6 Billion, While China is Forecast to Grow at 11.1% CAGR
The Radiopharmaceuticals market in the U.S. is estimated at US$1.6 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2027 trailing a CAGR of 11% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.9% and 6.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.
Beta Emitters Segment to Record 8.9% CAGR
In the global Beta Emitters segment, USA, Canada, Japan, China and Europe will drive the 8.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$677.9 Million in the year 2020 will reach a projected size of US$1.2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.3 Billion by the year 2027, while Latin America will expand at a 10.4% CAGR through the analysis period. We bring years of research experience to this 17th edition of our report. The 400-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Competitors identified in this market include, among others:
- Actinium Pharmaceuticals Inc.
- Alliance Medical
- Alseres Pharmaceuticals Inc.
- Avid Radiopharmaceuticals
- Bayer HealthCare, Radiology Division
- Bracco Diagnostics Inc.
- Cardinal Health, Inc.
- GE Healthcare
- Immunomedics, Inc.
- Ion Beam Applications SA
- Jubilant Pharma
- Lantheus Medical Imaging Inc.
- Medi-Radiopharma Ltd.
- Nordion, Inc.
- Peregrine Pharmaceuticals, Inc.
- PETNET Solutions Inc.
- Positron Corporation
- Triad Isotopes Inc.
The global analysis and forecast periods covered within the report are 2020-2027 (Current & Future Analysis) and 2012-2019 (Historic Review). Research estimates are provided for 2020, while research projections cover the period 2021-2027.
I. INTRODUCTION, METHODOLOGY & REPORT SCOPE
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession
Recent Market Activity
Current & Future Analysis
Diagnostic Radiopharmaceuticals: The Dominant Segment
Select Cardiology and Oncology Radiopharmaceuticals
New Therapeutic Radiopharmaceuticals to Drive Global Market
Relevant Aspects of Radiopharmaceutical Production
Intra-operative Lymphatic Mapping (ILM): Creates New Opportunities for Radiopharmaceuticals in Cancer Detection
Global Competitor Market Shares
Radiopharmaceuticals Competitor Market Share Scenario Worldwide (in %): 2020 & 2029
2. FOCUS ON SELECT PLAYERS
Actinium Pharmaceuticals, Inc. (USA)
Alliance Medical (UK)
Alseres Pharmaceuticals, Inc. (USA)
Avid Radiopharmaceuticals (USA)
Bayer HealthCare Pharmaceuticals (Germany)
Bracco Diagnostics, Inc. (USA)
Cardinal Health, Inc. (USA)
GE Healthcare (UK)
Ion Beam Applications S.A (Belgium)
Immunomedics, Inc. (USA)
Jubilant Pharma (India)
Lantheus Medical Imaging Inc. (USA)
Medi-Radiopharma Ltd (Hungary)
Nordion, Inc. (Canada)
Peregrine Pharmaceuticals, Inc. (USA)
PETNET Solutions Inc. (USA)
Positron Corporation (USA)
Triad Isotopes, Inc. (USA)
3. MARKET TRENDS & DRIVERS
Rise in Incidence of Cancer - A Major Growth Driver
Cancer Prone Sites based on Age
Ageing Population - A Vital Demography
Global CVD Stats
Growing Acceptance in Cancer Treatment
Increasing Acceptance of Disease-Targeted Treatment
Growing Emphasis of Accurate Diagnosis
Expanding Molecular Imaging Applications
Stringent Regulatory Guidelines for Manufacture, Storage and Usage
Global Supply Shortages
Price Sensitivity & Competition from Alternatives
Lack of Dosage Standards for Pediatric Patients Limits Radiopharmaceutical Efficacy
Unfounded Fears of Radiation Exposure Hinder Growth
Bottlenecks in Developing Markets
Recognition of Intrinsic Cost Benefits: Critical to Market Acceptance
Increasing Uptake of PET: A Prime Growth Driver
Non-Reactor Based TC-99m Production to Drive SPECT Growth
New Radiopharmaceuticals Drive Adoption of Molecular Imaging
PET and SPECT in Cardiovascular Imaging
Innovative Radiotracers - Key to PET & SPECT Success in Cardiovascular Imaging
Cardiac Amyloidosis Visualization - A Potential Application for PET
Application of PET in Drug Development to Expand Opportunities
Industry Focus Gears up for innovative Radiopharmaceuticals with Therapeutic Benefits
Innovative Radiopharmaceuticals to Boost Cardiac Applications
Personalized Medicine to Drive Nuclear Medicine
Rise in Incidence of Neurological Disorders to Drive Growth
Battling Alzheimer’s Disease - A Powerful Market Force for Nuclear Medicine
Combating the Shortage of RadioIsotopes
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
GEOGRAPHIC MARKET ANALYSIS
Market Facts & Figures
US Radiopharmaceuticals Market Share (in %) by Company: 2020 & 2025
Market Facts & Figures
European Radiopharmaceuticals Market: Competitor Market Share Scenario (in %) for 2020 & 2025
REST OF EUROPE
REST OF ASIA-PACIFIC
REST OF LATIN AMERICA
UNITED ARAB EMIRATES
REST OF MIDDLE EAST
Total Companies Profiled: 61